Research lab

The information contained in this page is intended for Malaysian healthcare professionals only.

Bringing About Personalized Innovation in Hemophilia Treatment

Thanks in part to hemophilia therapies currently available, life expectancy for hemophilia patients has increased on average to more than 60 years today.1 Baxter is committed to actively listening to and working with the hemophilia community to proactively shape the future of hemophilia by focusing on personalized innovations and solutions.

Baxter's range of management options allows clinicians to choose the appropriate product based on individual patient needs.

Specifically, Baxter is:

  • Supporting advocacy through community participation, including through patient and clinician education and expanding patient access to therapy
  • Advancing its portfolio through new therapies to address unmet market needs
  • Top

Training Programs

To help ensure a thriving community of hemophilia researchers and clinicians, Baxter recognizes the importance of supporting and promoting those currently working in the field and future leaders, including support through the funding of grants and fellowship programs in hemophilia and coagulation disorders. These programs include:

  • NHF Clinical Fellowship Program in Bleeding Disorders Research
  • Training in Bleeding Disorders for Healthcare Providers - A CDC training program for providers in Treatment Centers
  • Provider Shadow Program (at Rush University Medical Center in Chicago)
  • Sponsorship of Continued Medical Education (CME)

  • Top

Continuing Education

Our commitment to care continues through grants that support the creation of independent educational programs and symposia.


1. Darby SC, Kan SW, Spooner RJ, et.al, Mortality Rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not affected with HIV. Blood. 2007; 110: 815-825

Contact Us

Phone: 603-2267-6000
Fax: 603-2283-1784

Business hours: 8.30am-5.30pm MYT